Celularity (NASDAQ: CELU) and Vesalius Longevity Labs (CSE: VLAB) have announced an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S. final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (APIs).
According to Celularity, the collaboration expands its regenerative longevity platform by applying its U.S.-based manufacturing infrastructure and technical capabilities to support the development of Vesalius’s Peptual-branded peptide APIs at its Florham Park, New Jersey facility.
In a statement, Robert J. Hariri, MD, PhD, founder, chairman and CEO of Celularity, commented, “Peptides represent an important category of products which can work to augment the clinical utility of conventional therapeutics, and we believe can complement our regenerative cellular products. We have invested in a purpose-built U.S. facility and assembled a team with experience manufacturing complex medicines. As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our regenerative longevity strategy.”
Pradeep Albert, CEO of Vesalius, added, “We selected Celularity because its facility, technical personnel and experience manufacturing complex biological products provide a strong foundation for our peptide API sourcing plans. Celularity’s capabilities complement our Peptual platform and commercialization strategy. Together, we aim to establish a U.S. domestic supply platform supported by documented manufacturing processes, defined quality specifications and traceability from supplier inputs through final API release.”
